FGEN Share Price Performance

FGEN Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Simplifying Operations And Advancing FG-3246 Will Secure Future Success
Key Takeaways Strategic cost reductions and the sale of FibroGen China enhance financial stability, extending cash runway and potentially boosting overall financial performance. Focus on high-value oncology, including FG-3246 and roxadustat, positions the company for future revenue growth and increased market opportunities.
US$58.77
FV
88.3% undervalued intrinsic discount
60.01%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
3 months ago author updated this narrative

View all narratives

Recent FGEN News & Updates

No updates

FibroGen, Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -29.89
Gross Margin: -798.34%
Net Profit Margin: -1,726.96%
Debt/Equity Ratio: -52.1%

View full report ›

FibroGen, Inc. Competitors

View more competitors

About FGEN

Founded: 1993
Employees: 225
CEO: Thane Wettig
WebsiteView website: www.fibrogen.com

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

U.S. Market Performance

7 Days: -2.7%
3 Months: 10.1%
1 Year: 17.7%
Year to Date: 5.9%

In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

FibroGen Stock Price